Merck's SpringWorks takeover delivers a drug approval Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.

#MerckKGaA's acquisition of #SpringWorks has only just closed, but has already added a #newmedicine to its portfolio as it gets an EU approval for #raredisease therapy Ezmekly.

pharmaphorum.com/news/mercks-...

Rowley Law PLLC Investigates Proposed Acquisition of SpringWorks Therapeutics, Inc. by Merck KGaA Rowley Law PLLC is looking into alleged securities law violations by SpringWorks Therapeutics, Inc. following its planned acquisition by Merck KGaA.

Rowley Law PLLC Investigates Proposed Acquisition of SpringWorks Therapeutics, Inc. by Merck KGaA #United_States #New_York #Rowley_Law #Merck #SpringWorks

Belén Garijo: Merck Group acquires SpringWorks Therapeutics for €3 billion - OncoDaily Belén Garijo highlights Merck Group’s €3 billion acquisition of SpringWorks Therapeutics, marking the company’s largest planned healthcare acquisition in two decades.

Merck Group acquires SpringWorks Therapeutics for €3 billion - Belén Garijo

@merckgroup.bsky.social

oncodaily.com/blog/merck-g...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Merck #SpringWorks

Merck agrees $3.9 billion takeover of SpringWorks Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.

NEWS: #MerckKGaA has reached an agreement with #SpringWorks on a $47-per-share takeover deal that values the US #biotech at $3.9 billion.

pharmaphorum.com/news/merck-a...

Germany’s Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks By Ludwig Burger FRANKFURT (REUTERS) -German healthcare and materials group Merck (NSE:PROR) KGaA has struck a deal, it said on Monday, to acquire U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to boost its cancer drug business. The company based in Darmstadt, Germany, said the purchase price of $47 per share in cash represents an equity value of about $3.9 billion, equivalent to an enterprise value of $3.4 billion (3.0 billion euros), when SpringWorks’ cash holdings are deducted. Family-controlled Merck said last week the two companies were in late-stage discussions over a bid of around $47 per SpringWorks share. It will be funded with available cash and new debt and is expected to be accretive to Merck’s earnings per share, adjusted for special items, in 2027, a statement from the German group said. It added it would still be able to pursue larger transactions. It has two products on the market: Ogsiveo with 2024 sales of $172 million to treat desmoid tumours, an aggressive disease affecting soft tissue, as well as Gomekli, which was approved in February to treat NF1-PN, characterised by nerve sheath tumours.

Click Subscribe #Merck #SpringWorks #Biotech #Healthcare #CancerResearch

Germany’s Merck to buy SpringWorks for $3.9 bln Investing.com-- German biopharma firm Merck KGaA (ETR:MRCG) said on Monday it had entered a definitive agreement to buy U.S.-based peer SpringWorks Therapeutics Inc (NASDAQ:SWTX) for an equity value of $3.9 billion, after it last week confirmed it was in late-stage talks over the deal. Merck said in a press release it will pay about $47 for each share in Springworks, representing a premium of roughly 5% over SpringWorks’ Friday close. The figure values Springworks at about $3.9 billion. The German biopharma firm said the deal was a step towards diversifying its portfolio and increasing its presence in the United States. “Beyond this planned transaction, we will continue to explore M&A opportunities across our three complementary business sectors, always with a firm focus on strategic fit, financial robustness, and long-term value creation,” Merck Chair and CEO Belen Garijo said. Merck had last week confirmed it was in late-stage talks with Springworks over the deal. The acquisition is centered around Springworks’ large drug portfolio, which is expected to help spruce up Merck’s sales, especially as demand for its cancer drug Bavencio slowed in recent quarters. Merck also faces a loss of exclusivity for several other drugs, which present earnings headwinds. Springworks focuses on drugs to treat rare cancers and genetic disorders. Its genetic disorder drug Gomekli was approved by the U.S. Food and Drug Administration in February. Reports of Merck’s takeover plans had first broken in February this year, sending Springworks’ shares as high as $61.

Click Subscribe #Merck #SpringWorks #Acquisition #Investment #FinanceNews

I was wrong. German #Merck to acquire #Springworks for $47 a share.

Springwork was advised by #Centerview and #Goldman.

www.globenewswire.com/news-release...

What is amazing that options premiums imploded right after WSJ article + #Merck press release talked about a $47 'basis'. Nothing from $SWTX.

1st, 'basis', 2nd, takes 2 to tango. #SpringWorks

Merck puts a price on its SpringWorks takeover bid Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share.

NEWS: Reacting to press speculation, #Merck KGaA has acknowledged that talks to buy US biotech #SpringWorks are now in the late stages and are revolving around an offer of around $47 per share. #takeoverbid

pharmaphorum.com/news/merck-p...

Click Subscribe #Merck #SpringWorks #Pharmaceuticals #Biotechnology #BusinessNews

SpringWorks Therapeutics springs higher as Merck KGaA takeover said close Investing.com -- Shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close. This afternoon, The Wall Street Journal reported that the two companies are near a $47 per share takeover deal and a definitive agreement could be announced as soon as Monday, citing people familiar with the matter. Shares of SpringWorks last traded up 8% to $44.50. The potential deal has been in the works since at least February, when Merck KGaA confirmed it was in advanced talks to acquire the cancer and rare diseases drugmaker. Earlier in the week, an analyst at Barclays highlighted that a just-concluded CHMP meeting on SpringWorks’ Ogsiveo could help de-risk the potential deal. EU approval of Ogsiveo is seen as a key catalyst for a takeover. Ogsiveo is the first FDA-approved therapy for patients with desmoid tumors who require systemic treatment. The drug was approved by the FDA in November 2023.

Click Subscribe #SpringWorks #MerckKGaA #BiotechNews #PharmaIndustry #StockMarket